External validation of Pentafecta in patients undergoing laparoscopic radical cystectomy: results from a high-volume center.

ABSTRACT:

Background

To investigate whether Pentafecta is suitable for bladder cancer patients receiving laparoscopic radical cystectomy (LRC).

Methods

From November 2013 to December 2020, muscle invasive Bladder Cancer (MIBC) and non-muscle invasive Bladder Cancer (NMIBC) patients who received LRC and urinary diversion were retrospectively analyzed. Pentafecta was defined as meeting five criteria: negative soft margin, ≥ 16 lymph nodes (LNs) removed, major complications free, urinary diversion related sequelae free and clinical recurrence free within 1 year. Analyze the achievement of five criteria and compare the overall survival (OS) of Pentafecta group with non-attainment group. Multivariable Cox's regression was performed to evaluate the impact of Pentafecta on OS. Multivariable

SUBMITTER: Li K 

PROVIDER: S-EPMC8939065 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature